3Fagien S.Botox for the treatment dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery[J].Plast Reconstr Surg,1999,103(2): 701.
4Paloma V,Samper A.A Complication with the aesthetic use of Botox: herniation of the orbital fat[J].Plastic Reconstr Surg,2001,107(5): 1315.
5Moore AP,Wood GD.The medical management of masseteric hypertrophy with botulinum toxin type A[J].Br J Oral Maxil lofac Surg,1994,32(1):26-28.
6Kim HJ,Yum KW,Lee SS,et al.Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement[J].Dermatol Surg,2003,29(5):484-489.
7Lee HJ,Lee DW,Park YH,et al.Botulinum toxin a for aesthetic contouring of enlarged medial gastrocnemius muscle[J].Dermatol Surg,2004,30(6):867-871.
8Dressler D,Bigalke H.Antibody-induced failure of botulinum toxin type B therapy in de novo patients[J].Eur Neurol,2004,52(3):132-135.
9Agbenyega ET.Wareham AC.Effect of clenbuterol on skeletal muscle atrophy in mice induce by the glucocorticoid dexamethasone[J].Comp Biochem Physiol,1992,102(1):144-145.
10Ma K.,Mallidis C.,Bhasin S.et al.Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression[J].Am J Physiol Endocrinol Metab,2003,285:363-371.
